Ignite Creation Date:
2024-05-06 @ 7:48 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02604342
Status:
COMPLETED
Last Update Posted:
2019-10-29
First Post:
2015-11-11
Brief Title:
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase ALK-Positive Advanced Non-Small Cell Lung Cancer NSCLC Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Organization Data
Organization:
Hoffmann-La Roche
Class:
INDUSTRY
Study ID:
MO29750
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hoffmann-La Roche
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None